An open-label study to determine the maximum tolerated dose of the multitargeted tyrosine kinase inhibitor CEP-11981 in patients with advanced cancer

Background This phase I study evaluated the pharmacokinetics and pharmacodynamics of CEP-11981, an oral vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor, in patients with advanced, relapsed, or refractory solid tumors. Methods Oral CEP-11981 dose escalations followed a modified Fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Pili, Roberto, Carducci, Michael, Brown, Peter, Hurwitz, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226840/
https://www.ncbi.nlm.nih.gov/pubmed/25152243
http://dx.doi.org/10.1007/s10637-014-0147-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226840/
https://www.ncbi.nlm.nih.gov/pubmed/25152243
http://dx.doi.org/10.1007/s10637-014-0147-9

Ejemplares similares